FONTANINI, GABRIELLA
FONTANINI, GABRIELLA
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer
2015 L. Fornaro, P. Faviana, V. DE GREGORIO, C. Vivaldi, E. Paolicchi, G. Masi, F. Loupakis, E. Sensi, C. Lupi, G. Fontanini, Y. Wang, R. Danesi, A. Falcone, F. Crea
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo
2014 A. Antonelli, G. Bocci, C. LA MOTTA, S. Ferrari, P. Fallahi, A. Corrado, A. Fioravanti, S. Sartini, P. Orlandi, S. Piaggi, A. Corti, G. Materazzi, D. Galleri, S. Ulisse, G. Fontanini, R. Danesi, F. DA SETTIMO PASSETTI, P. Miccoli
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan
2014 F. Loupakis, C. Cremolini, A. Fioravanti, P. Orlandi, L. Salvatore, G. Masi, M. Schirripa, T. DI DESIDERO, C. Antoniotti, B. Canu, P. Faviana, E. Sensi, C. Lupi, G. Fontanini, F. Basolo, A. DI PAOLO, R. Danesi, A. Falcone, G. Bocci
Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1
2013 T. DI DESIDERO, A. Fioravanti, P. Orlandi, C. B., R. Giannini, N. Borrelli, M. S., X. P., G. Fontanini, F. Basolo, K. R. S., F. G., R. Danesi, G. Bocci
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo
2012 A. Antonelli, G. Bocci, C. LA MOTTA, S. Ferrari, P. Fallahi, I. Ruffilli, A. Di Domenicantonio, A. Fioravanti, S. Sartini, M. Minuto, S. Piaggi, A. Corti, G. Alì, T. Di Desidero, P. Berti, G. Fontanini, R. Danesi, F. DA SETTIMO PASSETTI, P. Miccoli
Functional characterization of EZH2 single nucleotide polymorphism and correlation of EZH2 expression with clinico-pathological and molecular parameters in colorectal (CRC) cancer samples
2012 C. Vivaldi, F. Crea, L. Fornaro, P. Faviana, G. Masi, V. DE GREGORIO, E. Paolicchi, E. Sensi, C. Lupi, G. Fontanini, R. Danesi, A. Falcone
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo
2011 C. B., A. Fioravanti, P. Orlandi, T. DI DESIDERO, A. G., G. Fontanini, A. DI PAOLO, T. M. D., R. Danesi, G. Bocci
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer
2011 A. Antonelli, G. Bocci, C. LA MOTTA, S.M. Ferrari, P. Fallahi, A. Fioravanti, S. Sartini, M. Minuto, S. Piaggi, A. Corti, G. Alì, P. Berti, G. Fontanini, R. Danesi, F. DA SETTIMO PASSETTI, P. Miccoli
Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients
2011 T. C., G. E., V. E., L. Boldrini, G.R. M. I., B. I., I. R., R. Danesi, C. F., P. G. J., G. Fontanini
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients
2010 L. F., C. Cremolini, F. A., L. C., F. I., O. P., S. E., C. B., S. L., D.D. T., M. G., G. Fontanini, R. Danesi, G. Bocci, A. Falcone
CIRCULATING AMPHIREGULIN (AR) PLASMA LEVELS AS SURROGATE PHARMACODYNAMIC MARKERS OF EGFR INHIBITION WITH CETUXIMAB IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
2010 C. Cremolini, F. Loupakis, A. Fioravanti, C. Lupi, P. Orlandi, L. Salvatore, G. Fontanini, R. Danesi, G. Bocci, A. Falcone
Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients
2006 F. Amatori, A. DI PAOLO, M. DEL TACCA, G. Fontanini, F. Vannozzi, L. Boldrini, G. Bocci, M. Lastella, R. Danesi